Drugs / ADG106
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04501276 | Sep 2020 → Jan 2024 | — | Adagene Inc | Completed | No outcome recorded |
| Phase 1 | NCT03802955 | Dec 2018 → Nov 2021 | cancer, non-Hodgkin lymphoma | Adagene, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03707093 | Sep 2018 → Jan 2022 | non-Hodgkin lymphoma | Adagene Inc | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05491083 | Jun 2023 → Dec 2026 expected | triple-negative breast carcinoma | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05275777 | May 2022 → Dec 2027 expected | Her2-receptor negative breast cancer | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05236608 | Nov 2021 → May 2024 | non-small cell lung carcinoma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT04645069 | Mar 2021 → Jan 2024 | — | Adagene Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT04775680 | Mar 2021 → Feb 2023 | cancer, non-Hodgkin lymphoma | Adagene, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADG106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04775680 ↗ |
| Action | Activate | “By binding to CD137, the study drug is expected to enhance the activity of activated T cells” NCT03707093 ↗ |
| Modality | Monoclonal antibody | “ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb.” NCT03707093 ↗ |
| Route | Intravenous | “IV infusion over 60 minutes on Day 1 of each cycle” NCT03707093 ↗ |
| Target | TNFRSF9 | “anti-CD137 IgG4 mAb” NCT04501276 ↗ |